- Home
- YOUL vs MGNX Comparison
YOUL vs MGNX Comparison
Compare YOUL & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YOUL | MGNX |
|---|---|---|
| Founded | N/A | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.2M | 115.8M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | YOUL | MGNX |
|---|---|---|
| Price | $1.13 | $1.98 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.20 |
| AVG Volume (30 Days) | 60.6K | ★ 590.5K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $149,962,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 155.26 |
| 52 Week Low | $0.78 | $0.99 |
| 52 Week High | $4.40 | $2.50 |
Technical Indicators
Market Signals| Indicator | YOUL | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 68.22 |
| Support Level | $1.09 | $1.61 |
| Resistance Level | $1.95 | $2.18 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 23.08 | 92.77 |
Price Performance
Historical ComparisonAbout YOUL Youlife Group Inc. American Depositary Shares
Youlife Group Inc is a blue-collar lifetime service provider with a nationwide network of 25 vocational schools under school management model and 25 curriculum development projects, covering a total of 37 cities or counties under 16 provinces of China.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.